PharmaNews.eu
  • Home
  • Business
  • R&D
  • EC
  • EMA
  • Events
  • Open Calls

Genzyme

Genzyme

Genzyme Corp.Genzyme has pioneered the development and delivery of transformative therapies for patients affected by rare and debilitating diseases for over 30 years. We accomplish our goals through world-class research and with the compassion and commitment of our employees. With a focus on rare diseases and multiple sclerosis, we are dedicated to making a positive impact on the lives of the patients and families we serve. That goal guides and inspires us every day. Genzyme's portfolio of transformative therapies, which are marketed in countries around the world, represents groundbreaking and life-saving advances in medicine. As a Sanofi company, Genzyme benefits from the reach and resources of one of the world's largest pharmaceutical companies, with a shared commitment to improving the lives of patients.

About Sanofi
Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

.

Genzyme RSS Channel

Filters
List of articles in category Genzyme
Title Published Date
Genzyme Receives Company Award from European Organisation for Rare Diseases (EURORDIS) 27 February 2013
Sanofi and its Subsidiary Genzyme to Feature More than 20 Data Presentations 18 October 2011
Genzyme and Isis Announce Submission of European Marketing Authorization Application for Mipomersen (Kynamro®) 28 July 2011
Mipomersen Data Presented at European Atherosclerosis Society Congress 29 June 2011
Genzyme Reports Financial Results for the Third Quarter of 2010 21 October 2010
Data from Mipomersen Phase 3 Trial in heFH Patients Presented at ESC 02 September 2010
Genzyme and Isis Report Results of Two Phase 3 Trials of Mipomersen 05 August 2010
Study Meets Primary Endpoint with 25 Percent LDL Reduction in Very High-Risk Patient Population 18 November 2009
European Commission Approves Genzyme's Mozobil 06 August 2009
Genzyme Receives European Approval of Renvela for Patients with Chronic Kidney Disease 15 June 2009
Genzyme Receives Positive Opinion for European Approval of Mozobil 30 May 2009
Genzyme Reports Solid Financial Results for the First Quarter of 2009 23 April 2009
European Authorities Approve Larger-Scale Production of Genzyme's Myozyme 26 February 2009
Strong Fourth Quarter for Genzyme Concludes Productive Year 11 February 2009
Genzyme Reports Strong Fourth-Quarter and 2008 Revenue Growth 13 January 2009
  1. You are here:  
  2. Home
  3. Genzyme

About

  • Home
  • Terms and Conditions
  • Contact

Advertise

Top News Channels

  • Business
  • Research
  • EMA
  • Events

Follow us

Didn't we got you connected? If not, please note the following magic buttons:

  • Facebook
  • Twitter
  • RSS 2.0
  • Atom 1.0

Newsletter

Stay updated on the latest Pharma News. Subscribe now, it's free!

Copyright © 2025 PharmaNews.eu. All Rights Reserved.